key: cord-0733949-7ltxvuqx
authors: Dettorre, Gino M.; Patel, Meera; Gennari, Alessandra; Pentheroudakis, George; Romano, Emanuela; Cortellini, Alessio; Pinato, David J.
title: The systemic pro-inflammatory response: targeting the dangerous liaison between COVID-19 and cancer
date: 2021-04-08
journal: ESMO Open
DOI: 10.1016/j.esmoop.2021.100123
sha: 1f6663158c9e0778539e314def11db322aa520cc
doc_id: 733949
cord_uid: 7ltxvuqx

Inflammation is an established driver of severe SARS-CoV-2 infection and a mechanism linked to the increased susceptibility to fatal COVID-19 demonstrated by patients with cancer. As patients with cancer exhibit a higher level of inflammation compared to the general patient population, patients with cancer and COVID-19 may uniquely benefit from strategies targeted at overcoming the unrestrained pro-inflammatory response. Targeted and non-targeted anti-inflammatory therapies may prevent end-organ damage in SARS-CoV-2-infected patients with cancer and decrease mortality. Here, we review the clinical role of selective inhibition of pro-inflammatory interleukins, tyrosine kinase modulation, anti-TNF agents, and other non-targeted approaches including corticosteroids in their roles as disease-modulating agents in patients with COVID-19 and cancer. Investigation of these therapeutics in this highly vulnerable patient group is posited to facilitate the development of tailored therapeutics for this patient population, aiding the transition of systemic inflammation from a prognostic domain to a source of therapeutic targets.

59 D u ra tio n a n d tim in g o f 2 6 1 th e a n ti-in fla m m a to r y re s p o n s e a re lin k e d to o u tc o m e s in p a tie n ts w ith in fe c tio u s 2 6 2 d is e a s e s . 59 2 6 3 I m p o r ta n tly , in te rle u k in s ig n a lin g is re d u n d a n t a n d p le io tr o p ic ; th e re fo re , in h ib itio n o f 2 6 4 a s in g le p a th w a y m a y n o t r e s u lt in c lin ic a l b e n e fit. 60 W h e th e r c a n c e r p a tie n ts m a y r e p r e s e n t a p o p u la tio n e x q u is ite ly s e n s itiv e to I L -6 2 6 8 in h ib itio n re m a in s to b e a s c e rta in e d . 2 6 9 J o u r n a l P r e -p r o o f J a n u s k in a s e ( J A K ) in h ib ito rs a r e a w e ll-e s ta b lis h e d th e ra p e u tic c la s s u tiliz e d in a 3 1 5 ra n g e o f a u to im m u n e a n d in fla m m a to r y d is e a s e s . 71 J A K a c tiv a tio n is c ritic a l fo r 3 1 6 tra n s c rip tio n o f c y to k in e s v ia d o w n s tr e a m a c tiv a tio n o f s ig n a l tra n s d u c e rs a n d a c tiv a to rs 3 1 7 o f tra n s c r ip tio n ( S T A T ) ; n e c e s s a r y fo r c e ll d iffe re n tia tio n a n d h e m a to p o ie s is ; a n d h a s 3 1 8 b e e n lin k e d in its c o n s titu tiv e ly a c tiv a te d fo r m s to le u k e m ia d e v e lo p m e n t v ia c a n c e r c e ll 3 1 9 p r o life ra tio n .

72 J A K in h ib ito rs a tte n u a te in fla m m a tio n in rh e u m a to id a rth ritis th ro u g h 3 2 0 re d u c tio n o f c y to k in e a n d in fla m m a to r y e le m e n t tra n s c rip tio n a n d a re b e in g e x p lo r e d a s 3 2 1 th e r a p e u tic s fo r le u k e m ia s d u e to in h ib itio n o f le u k e m ic c e ll p ro life ra tio n a n d re d u c tio n 3 2 2 o f th e n e o p la s m -in d u c e d in fla m m a to r y s ta te . 73 74 J A K in h ib ito rs a c c o r d in g ly m a y s e rv e 3 2 3 a s a n a n ti-C O V I D -1 9 th e r a p e u tic th r o u g h re d u c tio n o f c irc u la tin g c y to k in e s a n d 3 2 4 a d d itio n a lly c o n fe r p r e fe re n tia l b e n e fit fo r p a tie n ts w ith c o n c o m ita n t C O V I D -1 9 a n d 3 2 5 h e m a to lo g ic m a lig n a n c ie s a s s o c ia te d w ith a b e rra n t J A K s ig n a lin g . 72 74 T h e J A K in h ib ito r 3 2 6 ru x o litin ib , w h ic h e x h ib its a n tile u k e m ic a c tiv ity , h a s b e e n s tu d ie d fo r 75 T h e J A K 3 3 0 in h ib ito r b a ric itin ib , a th e r a p e u tic u tiliz e d fo r a n ti-in fla m m a to r y e ffe c ts in rh e u m a to id 3 3 1 a rth r itis , h a s b e e n s tu d ie d in c o m b in a tio n w ith th e a n tiv ira l re m d e s iv ir in p a tie n ts fe a tu re o f c a n c e r a n d s e v e re C O V I D -1 9 , p a tie n ts w ith c a n c e r m a y p r e fe re n tia lly b e n e fit 3 4 0 fro m J A K in h ib ito r th e r a p y fo r s e v e r e C O V I D -1 9 . 48 49 T h e U n iv e rs ity o f S o u th e r n 3 4 1 C a lifo rn ia ( U S C ) is re c ru itin g p a tie n ts to a s tu d y in v e s tig a tin g b a ric itin ib a lo n e a n d in T N F , a p ro -in fla m m a to r y c y to k in e fa m ily u p r e g u la te d in a u to im m u n e d is o rd e rs , 3 5 0 in fe c tio u s d is e a s e s , a n d c a n c e r , re g u la te s th e e x p r e s s io n o f re a c tiv e o x y g e n s p e c ie s 3 5 1 ( R O S ) a n d o th e r p ro -in fla m m a to r y c y to k in e s th ro u g h th e n u c le a r fa c to r k a p p a -lig h t-3 5 2 c h a in -e n h a n c e r o f a c tiv a te d B c e lls ( N F -κ B ) a n d a c tiv a to r p ro te in 1 ( A P -1 ) p a th w a y s . 87 N o d a ta e x is ts fo r p a tie n ts w ith c a n c e r a n d C O V I D -3 8 1 1 9

re c e iv in g a n ti-T N F th e ra p y a s a C O V I D -1 9 th e r a p e u tic . P a tie n ts w ith 3 8 2 rh e u m a to lo g ic a l d is e a s e s h a v e c o m p ris e d th e c u rr e n t fo c u s o f a n ti-T N F th e ra p y a n d 3 8 3 im p lic a tio n s fo r C O V I D -1 9 d is e a s e c o u rs e d u e to c o n c e r n s r e g a r d in g th is 3 8 4 im m u n o s u p p re s s iv e tr e a tm e n t a n d C O V I D -1 9 ris k . 87 P a tie n ts w ith c a n c e r a n d C O V I D -3 8 5 1 9 w a rr a n t s tu d y a s T N F im b a la n c e s u p p o rts tu m o r in itia tio n , in v a s io n , a n d m e ta s ta s is 3 8 6 a n d is a n o te d s e r o lo g ic a l m a rk e r o f s e v e r e C O V I D -1 9 .

90 A n ti-T N F tr e a tm e n t m a y 3 8 7 e x te n d p r e fe re n tia l b e n e fit to p a tie n ts w ith c a n c e r a n d m a n a g e m e n t a s T N F e x h ib its b o th p ro -a n d a n ti-tu m o r a l e ffe c ts .

83 W h ile s h o rt-te rm a n ti-3 9 0 T N F tre a tm e n t h a s n o t b e e n a s s o c ia te d w ith c a n c e r p r o g re s s io n , th e e ffe c ts o f a n ti-T N F 3 9 1 th e r a p ie s in p a tie n ts w ith c a n c e r a n d in fe c tio u s d is e a s e r e m a in to b e te s te d . 84 A s e a rc h 3 9 2 o n C lin ic a lT ria ls . g o v re v e a le d n o c lin ic a l tria ls c u rr e n tly in v e s tig a tin g a n ti-T N F tre a tm e n t 3 9 3 s p e c ific a lly fo r p a tie n ts w ith c a n c e r a n d C O V I D -1 9 . re s u ltin g fro m c o n c o m ita n t re c e ip t o f s te ro id a l a n d a n ti-c a n c e r th e ra p e u tic s in p a tie n ts 4 4 0 w ith c a n c e r a n d C O V I D -1 9 .

100-102 F u rth e r s tu d y w ill re v e a l d iffe re n c e s in im m u n e s y s te m 4 4 1 re s p o n s e b e tw e e n p a tie n ts w ith c a n c e r a n d th e g e n e ra l p a tie n t p o p u la tio n . re le a s e b y in te rfe re n c e o f th e a n tim a la ria l a g e n ts w ith a n tig e n p ro c e s s in g a n d 4 4 8 a u to a n tig e n p r e s e n ta tio n . 103 116 P a tie n ts w ith c a n c e r a n d C O V I D -1 9 m a y 4 9 6 p r e fe re n tia lly b e n e fit fro m c o lc h ic in e tre a tm e n t c o m p a re d to th e g e n e ra l p o p u la tio n a s 4 9 7 a c tiv ity , a n d in fe c te d d e n d r itic c e ll a c tiv ity . to e x h a u s te d , o r h y p o re s p o n s iv e , T c e lls is a w e ll-k n o w n d e te rm in a n t o f p ro g n o s is in 5 2 1 p a tie n ts w ith a d v a n c e d m a lig n a n c ie s . 35 129 130 I t c a n th e r e fo re b e h y p o th e s iz e d th a t 5 2 2 p a tie n ts w ith c a n c e r a n d C O V I D -1 9 m a y p r e fe re n tia lly b e n e fit fro m T α 1 tre a tm e n t o v e r 5 2 3 th e g e n e r a l p a tie n t p o p u la tio n th r o u g h r e d u c tio n o f s y n e rg is tic T c e ll e x h a u s tio n fro m 5 2 4 b o th c a n c e r a n d C O V I D -1 9 . T h e p h a s e 2 P R O T H Y M O S s tu d y is c u rre n tly in v e s tig a tin g 5 2 5

T α 1 a s p r o p h y la x is fo r p a tie n ts w ith c a n c e r a n d s e v e r e C O V I D -1 9 .

131 C o n c lu s io n o f th is 5 2 6 s tu d y a n d c o m p a r a tiv e in v e s tig a tio n b e tw e e n p a tie n ts w ith C O V I D -1 9 w ith o r w ith o u t 5 2 7 h is to r y o f c a n c e r w ill h e lp c la rify w h e th e r a ro le e x is ts fo r th is th e ra p y in p a tie n ts w ith 5 2 8

C O V I D -1 9 a n d c a n c e r. B 7 a n d p r o g r a m m e d d e a th -lig a n d 1 ( P D -L 1 ) , in h ib itin g a n tig e n p r e s e n ta tio n a n d 5 3 6 c o n s e q u e n t T c e ll re s p o n s e .

132 I n o n c o lo g ic d is e a s e , th e s e r e g u la to rs p re v e n t a n ti-5 3 7 tu m o r a c tiv ity a n d c a n c e r c e ll e lim in a tio n b y T c e lls a s s o m e c a n c e r c e lls e x p re s s 5 3 8 s u rfa c e B 7 a n d P D -L 1 .

132 F irs t u tiliz e d fo r m e ta s ta tic m e la n o m a , im m u n e c h e c k p o in t 5 3 9 in h ib ito rs ( I C I ) a im to re s to re a n ti-c a n c e r T c e ll re a c tiv ity th r o u g h a n tib o d y in h ib itio n o f 5 4 0 C T L A -4 /B 7 b in d in g a n d P D -1 /P D -L 1 b in d in g .

133 A s s e v e re C O V I D -1 9 m a y c a u s e T c e ll 5 4 1 e x h a u s tio n , I C I s h a v e b e e n p o s tu la te d to re s to re T c e ll fu n c tio n in c ritic a lly ill p a tie n ts ; 5 4 2 h o w e v e r, o n ly o b s e r v a tio n a l re g is trie s o f p a tie n ts w ith C O V I D -1 9 a n d c a n c e r 5 4 3 u n d e rg o in g I C I tre a tm e n t fo r o n c o lo g ic d is e a s e e x is t, a n d n o s tu d ie s fo r th e g e n e r a l 5 4 4 p a tie n t p o p u la tio n w ith C O V I D -1 9 e x is t. 134 C O V I D -1 9 a lre a d y r e c e iv in g I C I s fo r c a n c e r d id n o t p r e s e n t h ig h e r m o rta lity th a n 5 5 4 p a tie n ts w ith c a n c e r a n d C O V I D -1 9 n o t r e c e iv in g I C I s a t tim e o f C O V I D -1 9 d ia g n o s is . 138 W h ile 5 5 9 o n g o in g I C I th e r a p y fo r c a n c e r d o e s n o t a p p e a r to in c r e a s e s u s c e p tib ility to fa ta l 5 6 0 C O V I D -1 9 , th e re a r e n o s tu d ie s o f I C I s a d m in is te re d a s a n ti-C O V I D -1 9 th e ra p e u tic s . 5 6 1 S tu d y o f I C I tre a tm e n t fo r S A R S -C o V -2 in fe c tio n in p a tie n ts w ith c a n c e r a n d C O V I D -1 9 5 6 2 n o t p r e v io u s ly re c e iv in g th is a n ti-n e o p la s tic th e ra p y w ill c la rify th e s a fe ty a n d u tility o f 5 6 3 I C I s fo r re v e rs a l o f T c e ll e x h a u s tio n in in fe c tio u s d is e a s e . P ro s p e c tiv e tria ls o f I C I s fo r 5 6 4 C O V I D -1 9 fo r th e g e n e ra l p a tie n t p o p u la tio n w ill e lu c id a te d iffe r e n c e s in im m u n e 5 6 5 re s p o n s e s a n d m e c h a n is m s o f T c e ll e x h a u s tio n b e tw e e n p a tie n ts w ith o r w ith o u t 5 6 6 J o u r n a l P r e -p r o o f T h e c h a lle n g e o f th e g lo b a l C O V I D -1 9 p a n d e m ic h a s p r o v e n th e u tility o f c ro s s -fie ld 6 1 2 c o lla b o r a tio n fo r d r u g r e p u r p o s in g a n d tre a tm e n t d e v e lo p m e n t.

136 142 I m m u n o -6 1 3 o n c o lo g is ts , e x p e rie n c e d w ith im m u n e -m o d u la tin g th e r a p e u tic s , h a v e b o th id e n tifie d 6 1 4 a n ti-c a n c e r d ru g s th a t m a y o ffe r th e ra p e u tic b e n e fit fo r C O V I D -1 9 a n d n o te d s im ila ritie s 6 1 5 b e tw e e n a n ti-c a n c e r tre a tm e n t a n d 

The significance of ferritin in cancer: anti-oxidation

Systemic proinflammatory response identifies patients with cancer with 6 8 2 adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflamm atory Score

Inflammation and reduced albumin synthesis associated with stable 6 8 5 decline in serum albumin in hem odialysis patients

Linkage of hypoalbuminemia, inflam mation, and oxidative stress in 6 8 8 patients receiving m aintenance hemodialysis therapy

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive 6 9 1 study

Hematological findings and complications of COVID-19

The prognostic significance of the prognostic nutritional index in cancer: a systematic 6 9 6 review and meta-analysis

Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply

Immune dysfunction in cancer patients

Imm une dysfunction following COVID-19, especially in severe patients

IL-6, cancer and cachexia: metabolic dysfunction creates the perfect storm

Can serum IL-6 levels predict sarcopenia and poor outcom e in 7 0 8 relapsed/refractory gynecologic cancer patients

Im pact of interleukin-6 in hematological malignancies

Inflam mation and cancer

Interferon gamma in cancer immunotherapy

TNF: a m aster switch for inflamm ation to cancer

Cytokine Storm s: Understanding COVID-19

Identification of Predictive Biom arkers for Cytokine Release Syndrome 7 2 1 after Chim eric Antigen Receptor T-cell Therapy for Acute Lym phoblastic Leukemia

Cytokine Storm s in Cancer and COVID-19

IL-6 produced by macrophages infected with Mycobacterium species 7 2 6 suppresses T cell responses

IL-6 in inflammation, immunity, and disease

IL-6 regulates neutrophil trafficking during acute inflammation via 7 3 0 STAT3

Systematic literature review of IL-6 as a biomarker or treatment target in 7 3 3 patients with gastric, bile duct, pancreatic and colorectal cancer

Interleukin-6 increases vascular endothelial growth factor and angiogenesis 7 3 6 in gastric carcinoma

IL-6 Activities in the Tumour Microenvironment

Im mune-suppressive effects of interleukin-6 on T-cell-mediated anti-7 4 2 tumor immunity

IL-6 signaling promotes tumor growth in colorectal cancer

Is IL-6 the best pro-inflammatory biomarker

Significance of interleukin-6 (IL-6) in breast cancer (review)

Cytokine release syndrom e in severe COVID-19: interleukin-6 receptor antagonist 7 5 2 tocilizumab may be the key to reduce mortality

FDA Approval Sum mary: Tocilizumab for Treatment of

Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Cytokine release syndrome in severe COVID-19

Toxicities of chim eric antigen receptor T cells: recognition and management

Toxicity Induced by a Bispecific T Cell-Redirecting Protein Is 7 6 2 Mediated by Both T Cells and Myeloid Cells in Immunocompetent Mice

Tocilizumab for patients with COVID-19 pneumonia. The single-arm

TOCIVID-19 prospective trial

Tocilizumab in Patients Hospitalized with Covid-19 Pneum onia

Tocilizum ab in patients with severe COVID-19: a retrospective 7 7 0 cohort study

COVACTA trial raises questions about tocilizumab's benefit in COVID-19

COVID-19: Give it time! Clin Infect Dis

Roche provides an update on the phase III COVACTA trial of Actemra/RoActemra in hospitalised

Interleukin-6 blockade with sarilumab in severe COVID-19 with systemic hyperinflamm ation: an open-label cohort study

Outcomes and biomarker analyses among patients with COVID-19 7 8 2 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

The compensatory anti-inflam matory response syndrome (CARS) in critically ill 7 8 5 patients

Insights from the Interleukin 6 Family of

Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review

Role of Bruton's tyrosine kinase in B cells and m alignancies

Ibrutinib and Venetoclax for First-Line Treatm ent of CLL

Occupy BTK: the key to controlling CLL

The BTK inhibitor ibrutinib may protect against pulmonary injury in 8 0 0 COVID-19-infected patients

Inhibition of Bruton tyrosine kinase in patients with severe 8 0 3 COVID-19

ACE2: Evidence of role as entry receptor for SARS-CoV-2 and im plications in 8 0 5 comorbidities

ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a

Differentiated Selectivity and In Vivo Potency Profile

Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer

JAK inhibitors for the treatment of autoimmune and inflam matory 8 1 6 diseases

The Janus kinases (Jaks)

Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on 8 2 1 the Em erging Clinical Data

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A 8 2 6 multicenter, single-blind, randomized controlled trial

Mechanisms Underlying the Anti-inflammatory and Im munosuppressive 8 2 9 Activity of Ruxolitinib

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with 8 3 2 refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

Baricitinib plus Rem desivir for Hospitalized Adults with Covid-19

Baricitinib: A Review in Rheum atoid

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

A com prehensive review of pacritinib in myelofibrosis

Tumor necrosis factor

The role of TNF in cancer

The Potential for Repurposing Anti-TNF as a Therapy for the Treatment 8 4 8 of COVID-19

Accumulating evidence suggests anti-TNF therapy needs to be given 8 5 1 trial priority in COVID-19 treatment

Modulation of TNF-alpha-converting enzym e by the spike 8 5 4 protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry

COVID-19 in patients with rheumatological diseases treated with anti-8 5 7 TNF

Recovery from COVID-19 in a patient with spondyloarthritis treated with 8 5 9 TNF-alpha inhibitor etanercept

Clinical course of COVID-19 in a series of patients with chronic arthritis 8 6 2 treated with immunosuppressive targeted therapies

Targeting TNF for Treatm ent of Cancer and Autoimm unity

Comparative cytotoxicity of dexam ethasone and prednisolone in childhood 8 6 9 acute lymphoblastic leukemia

Treatm ent of rheumatoid arthritis

Corticosteroids: Mechanisms of Action in Health and Disease

Corticosteroids for COVID-19: the search for an optimum duration of therapy

Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report

Association Between Adm inistration of Systemic Corticosteroids and Mortality Among 8 8 0 Critically Ill Patients With COVID-19: A Meta-analysis

Utilization of COVID-19 Treatments and Clinical Outcom es among 8 8 2 Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study

Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact 8 8 5 of type of cancer therapy and COVID therapy on survival

The effect of immunosuppressive chem otherapy on im mune function in 8 8 9 patients with malignant disease

Need to m anage drug safety (French Society for Oncology Pharm acy [SFPO] guidelines)

Hydroxychloroquine in COVID-19: Potential Mechanism of Action

Mechanisms of action of hydroxychloroquine and chloroquine: implications for 8 9 8 rheumatology

Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19

Risk of QT Interval Prolongation Associated W ith Use of

COVID-19)

Prolonged QTc interval in cancer therapeutic drug development: defining arrhythmic risk in 9 0 7 malignancy

Management of QT prolongation induced by anti-cancer drugs: Target 9 1 0 therapy and old agents. Different algorithms for different drugs

Colchicine as a possible therapeutic option in 9 1 3 COVID-19 infection

M echanism of action of colchicine in the treatment of gout

Anti-inflammatory therapy for COVID-19 infection: the case for colchicine

Colchicine--Update on m echanisms of action and therapeutic uses

The NLRP3 Inflammasome: An Overview of Mechanisms of Activation

Association between treatm ent with colchicine and improved survival 9 2 5 in a single-centre cohort of adult hospitalised patients with COVID-19 pneum onia and acute respiratory 9 2 6 distress syndrom e

Beneficial effects of colchicine for m oderate to severe COVID-19: a 9 2 9 randomised, double-blinded, placebo-controlled clinical trial

Effect of Colchicine vs Standard Care on Cardiac

Inflammatory Biom arkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease

The GRECCO-19 Random ized Clinical Trial

Colchicine Inhibits Neutrophil Extracellular Trap Form ation in Patients With

Acute Coronary Syndrome After Percutaneous Coronary Intervention

The emerging role of neutrophil extracellular traps in severe acute 9 3 9 respiratory syndrom e coronavirus 2 (COVID-19)

DNA of neutrophil extracellular traps promotes cancer m etastasis via CCDC25. 9 4 2

Role of the NLRP3 inflam masome in cancer

Targeting the NLRP3 Inflammasom e in Severe COVID-19

Immune M odulation with Thymosin Alpha 1 Treatm ent

Thym osin Alpha 1 Mitigates Cytokine Storm in Blood Cells From

Thymosin Alpha 1 Reduces the Mortality of Severe Coronavirus Disease 2019 by 9 5 3 Restoration of Lymphocytopenia and Reversion of Exhausted T Cells

Thymosin alpha 1 and HIV-1: recent advances and future 9 5 6 perspectives

Thymosin Alpha1-Fc Modulates the Im mune System and Down-regulates the 9 5 9 Progression of Melanoma and Breast Cancer with a Prolonged Half

Toll-like receptor signaling pathways

Thymosin alpha 1 restores NK-cell activity and prevents tumor 9 6 4 progression in mice im munosuppressed by cytostatics or X-rays

T-cell exhaustion in the tumor microenvironment

The right imm une-m odulation at the right time: thymosin alpha1 9 7 1 for prevention of severe COVID-19 in cancer patients

Imm une checkpoint blockade therapy for cancer: An overview of FDA-9 7 4 approved im mune checkpoint inhibitors

A decade of immune-checkpoint inhibitors in cancer therapy

COVID-19 and imm une checkpoint inhibitors: initial considerations

COVID-19 in patients with thoracic m alignancies (TERAVOLT): 9 8 1 first results of an international, registry-based, cohort study

Insights from immuno-oncology: the Society for Imm unotherapy of Cancer

Statem ent on access to IL-6-targeting therapies for COVID-19

Clinical im pact of COVID-19 on patients with cancer treated with 9 8 7 immune checkpoint inhibition

Impact of PD-1 Blockade on Severity of COVID-19 in Patients with Lung Cancers

Triage decision-making at the time of COVID-19 infection: the Piacenza 9 9 3 strategy

An inflamm atory cytokine signature predicts COVID-19 severity 9 9 6 and survival

6 0 2 E s p e c ia lly fo r p a tie n ts w ith a h e ig h te n e d ris k fo r s y n e rg is tic in fla m m a tio n , th is w o u ld a id 6 0 3 in ra p id d e te rm in a tio n o f th e ta rg e te d o r n o n -ta rg e te d th e r a p y to b e u tiliz e d . T o th is e n d , 6 0 4 th e C O V I D -1 9 a n tiv ira l re s p o n s e in a p a n -tu m o r im m u n e m o n ito rin g s tu d y ( C A P T U R E ) , 6 0 5 a p ro s p e c tiv e s tu d y r e c ru itin g p a tie n ts w ith c o n c o m ita n t c a n c e r a n d C O V I D -1 9 , a im s to 6 0 6 p r o file th e im m u n e r e s p o n s e s o f th e s e p a tie n ts to S A R S -C o V -2 in fe c tio n . 141 6 0 7 T r a n s la tio n a l s tu d ie s s im ila r to C A P T U R E w ill h e lp e s ta b lis h th e m o le c u la r fe a tu r e s 6 0 8 u n d e rly in g th e p r o g re s s io n o f C O V I D -1 9 in p a tie n ts w ith c a n c e r a n d fa c ilita te th e 6 0 9 d e v e lo p m e n t o f ta rg e te d a n d n o n -ta r g e te d a n ti-in fla m m a to r y a g e n ts in p a tie n ts w h o a r e 6 1 0